National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Liver (Hepatocellular) Cancer Screening (PDQ®)
Patient Version   Health Professional Version   Last Modified: 02/15/2008



What is screening?






General Information About Liver (Hepatocellular) Cancer






Liver (Hepatocellular) Cancer Screening






Risks of Liver (Hepatocellular) Cancer Screening






Get More Information From NCI






Changes to This Summary (02/15/2008)






Questions or Comments About This Summary






About PDQ



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Liver (Hepatocellular) Cancer Screening

Key Points for This Section


Tests are used to screen for different types of cancer.

Some screening tests are used because they have been shown to be helpful both in finding cancers early and in decreasing the chance of dying from these cancers. Other tests are used because they have been shown to find cancer in some people; however, it has not been proven in clinical trials that use of these tests will decrease the risk of dying from cancer.

Scientists study screening tests to find those with the fewest risks and most benefits. Cancer screening trials also are meant to show whether early detection (finding cancer before it causes symptoms) decreases a person's chance of dying from the disease. For some types of cancer, the chance of recovery is better if the disease is found and treated at an early stage.

Clinical trials that study cancer screening methods are taking place in many parts of the country. Information about ongoing clinical trials is available from the NCI Web site.

There is no standard or routine screening test for liver cancer.

Although there are no standard or routine screening tests for liver cancer, the following tests are being used or studied to screen for it:

Ultrasound

Ultrasound is a procedure in which high-energy sound waves (ultrasound) are bounced off the liver and make echoes. The echoes form a picture of the liver called a sonogram. The picture can be printed to be looked at later.

CT scan

CT scan is a procedure that makes a series of detailed pictures of the liver, taken from different angles. The pictures are made by a computer linked to an x-ray machine. A dye may be injected into a vein or swallowed to help the liver show up more clearly. This procedure is also called CAT scan or computed tomography.

Tumor markers

Tumor markers, also called biomarkers, are substances made by the tumor that may be found in the blood, other body fluids, or tissues. A high level of a specific tumor marker may mean that a certain type of cancer is present in the body.

Alpha-fetoprotein (AFP) is the most widely used tumor marker for detecting liver cancer. However, other cancers and certain conditions, including pregnancy, hepatitis, and other types of cancer, may also increase AFP levels.

Specific tumor markers that may lead to early detection of liver cancer are being studied.

Information about ongoing clinical trials is available from the NCI Web site.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov